Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Toray, Japan Tobacco and Torii Launches Oral Anti-itch Drug Remitch

This article was originally published in PharmAsia News

Executive Summary

Japanese companies Toray, Japan Tobacco and Torii Pharmaceuticals March 24 launched oral anti-itch drug Remitch (nalfurafine) capsule in Japan. Originated by Toray, nalfurafine is a selective kappa-opioid receptor agonist and the first oral anti-itching treatment in Japan for hemodialysis patients resistant to existing treatments. The drug obtained approval Janu. 21 and is currently marketed by Torii. The Japan Society for Dialysis Therapy estimates there are more than 275,100 dialysis patients in Japan. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts